查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1735632

全球白喉-破傷風-百日咳疫苗市場規模（依產品類型、年齡層、最終用戶、區域範圍和預測）

Global Diphtheria, Tetanus, and Acellular Pertussis Combined Vaccine Market Size By Product Type, By Age Group, By End-User, By Geographic Scope And Forecast
出版日期: | 出版商: Verified Market Research | 英文 202 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

白喉、破傷風、百日咳聯合疫苗市場規模的變遷及預測

2024 年白喉、破傷風和百日咳疫苗市場規模價值 5,500,460 億美元，預計到 2032 年將達到 8,232,550 億美元，2026 年至 2032 年的複合年成長率為 5.17%。

  • DTaP 疫苗是一種聯合疫苗，含有去活化的白喉梭菌和破傷風梭菌毒素或成分以及百日咳博德氏菌抗原。它通常作為常規兒童免疫接種的一部分，用於嬰幼兒。此疫苗可刺激人體免疫系統產生針對這些細菌病原體的抗體，從而提供免疫力並預防這些病原體引起的疾病。
  • 白喉是一種細菌感染疾病，可引起嚴重的呼吸道症狀和危及生命的併發症。 DTaP 疫苗透過刺激免疫系統產生抗體來中和白喉細菌產生的毒素，從而預防白喉。
  • 破傷風是一種細菌感染疾病，會影響神經系統，並導致肌肉僵硬和痙攣。 DTaP疫苗含有一種成分，可誘發身體對破傷風桿菌所產生的毒素產生免疫力。
  • 百日咳是一種以劇烈咳嗽為特徵的傳染性呼吸道感染疾病。 DTaP 疫苗含有百日咳博德氏菌抗原，可刺激人體產生抗體，進而預防百日咳感染。
  • 正在進行的研究旨在開發 DTaP 疫苗的改良配方，以提高效力、安全性和保護時間，包括開發新的佐劑、遞送系統和抗原組合，以最佳化免疫反應並減少副作用。

白喉-破傷風-百日咳疫苗市場動態

影響全球白喉破傷風百日咳疫苗市場的關鍵市場動態：

關鍵市場促進因素

  • 疫苗接種意識不斷增強：父母、看護者和醫療保健專業人員越來越意識到接種疫苗在預防白喉、破傷風和百日咳等疾病方面的重要性，在教育宣傳活動和公共衛生舉措的推動下，對 DTaP 疫苗的需求激增，從而擴大了市場。
  • 百日咳發病率上升：百日咳疫情的爆發源自於複雜的疾病傳播機制和群體免疫的挑戰。促成因素包括免疫力下降、疫苗接種覆蓋率不全、百日咳桿菌的演化。診斷困難導致治療延誤，並增加感染風險。百日咳患者數量的增加將推動市場成長。
  • 醫療保健支出不斷成長：新興經濟體醫療保健支出的不斷成長，正在鼓勵對預防措施（尤其是疫苗接種計劃）的投資。醫療保健機構透過與政府機構和國際組織的合作，廣泛確保疫苗接種和分發，尤其是在醫療資源匱乏和偏遠地區。對預防性健康措施（尤其是疫苗接種計劃）日益成長的投入，正在推動市場成長。
  • 疫苗製劑的進步：創新的製劑策略、佐劑、呈現抗原系統和增強的遞送機制提高了 DTaP 疫苗的性能，提高了其穩定性、保存期限和易用性，從而促進了其市場擴張。

主要挑戰

  • 疫苗供不應求：生產中斷，例如設備故障和品管問題，可能會阻礙DTaP疫苗的生產，並導致供應不足。供應鏈中斷，例如運輸延誤和儲存問題，可能會加劇供不應求，阻礙疫苗及時分發至醫療保健和疫苗接種點，並擾亂聯合疫苗的生產和交付。
  • 低溫運輸管理挑戰：低溫運輸管理對疫苗的有效性至關重要，但溫度波動可能會影響其有效性。電力、冷凍和交通基礎設施匱乏的偏遠地區在低溫運輸管理方面面臨更多挑戰。缺乏適當的處理通訊協定進一步限制了白喉-破傷風-百日咳疫苗市場的發展。
  • 成本問題：由於資源限制、供應有限、物流障礙和定價問題，白喉-破傷風-急性百日咳疫苗在低收入和中等收入國家難以取得。這可能會阻礙疫苗接種，並擴大免疫覆蓋缺口。醫療機構難以維持穩定的庫存，導致錯失為兒童（尤其是弱勢兒童）接種疫苗的機會。配送物流，尤其是在偏遠和服務不足的地區，可能會阻礙聯合疫苗市場的成長。

主要趨勢

  • 疫苗配方改進：DTaP 疫苗正在持續研究，以改善配方、安全性和保護持續時間。這包括研究新型佐劑、遞送機制和抗原組合，以最佳化免疫反應並最大程度地減少副作用，從而為市場成長創造機會。
  • 研究與發展：研究正在推進DTaP疫苗技術，以提高其有效性、安全性和可近性。 mRNA疫苗技術就是這樣一種技術，它利用合成的mRNA分子產生特異性抗原，引發強烈的免疫反應。這種方法具有快速開發、擴充性和免疫抗原性等優勢。此外，類病毒顆粒、脂質體和奈米顆粒載體等新型抗原遞送平台也正在研究中。
  • 聯合疫苗：人們對開發聯合疫苗（例如 DTaP 疫苗）的興趣日益濃厚，因為它們可能能夠透過單一配方提供對更廣泛感染疾病的保護。

目錄

第1章全球DTaP聯合疫苗市場簡介

  • 市場概覽
  • 研究範圍
  • 先決條件

第2章執行摘要

第3章：已驗證的市場研究調查方法

  • 資料探勘
  • 驗證
  • 第一手資料
  • 資料來源列表

第4章全球DTaP聯合疫苗市場展望

  • 概述
  • 市場動態
    • 驅動程式
    • 限制因素
    • 機會
  • 波特五力模型
  • 價值鏈分析

5.全球DTaP 聯合疫苗市場（依產品類型）

  • 概述
  • DTaP
  • TD
  • Tdap

6. 全球DTaP聯合疫苗市場（依年齡層）

  • 概述
  • 成人
  • 孩子們

7. 全球DTaP聯合疫苗市場（按最終用戶）

  • 概述
  • 醫院
  • 診所
  • 疫苗接種中心

8. 全球DTaP聯合疫苗市場（按地區）

  • 概述
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 其他歐洲國家
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 其他亞太地區
  • 世界其他地區
    • 拉丁美洲
    • 中東和非洲

9.全球DTaP聯合疫苗市場競爭格局

  • 概述
  • 各公司市場排名
  • 主要發展策略

第10章 公司簡介

  • Bionet-Asia
  • Johnson & Johnson
  • GlaxoSmithKline plc
  • Mass biologics
  • Meiji Holdings Co., Ltd.
  • Merck & Co., Inc.
  • Panacea Biotech Ltd.
  • Sanofi
  • Serum Institute of India Pvt. Ltd.
  • namely AJ Vaccines

第11章 公司簡介 附錄

  • 相關調查
簡介目錄
Product Code: 35919

Diphtheria, Tetanus And Acellular Pertussis Combined Vaccine Market Size And Forecast

Diphtheria, Tetanus And Acellular Pertussis Combined Vaccine Market size was valued at USD 5500.46 Million in 2024 and is projected to reach USD 8232.55 Million by 2032, growing at a CAGR of 5.17% from 2026 to 2032.

  • The DTaP vaccine is a combination vaccine that contains inactivated toxins or components of the diphtheria and tetanus bacteria, as well as antigens from the Bordetella pertussis bacterium. It is administered through a series of shots typically given to infants and young children as part of routine childhood immunization schedules. The vaccine stimulates the body's immune system to produce antibodies against these bacterial pathogens, providing immunity and protection against the diseases they cause.
  • Diphtheria is a bacterial infection that can cause severe respiratory symptoms and potentially life-threatening complications. The DTaP vaccine helps prevent diphtheria by stimulating the immune system to produce antibodies that neutralize the toxins produced by the bacterium Corynebacterium diphtheriae.
  • Tetanus is a bacterial infection that affects the nervous system, leading to muscle stiffness and spasms. The DTaP vaccine includes a component that induces immunity against the toxin produced by the bacterium Clostridium tetani, which causes tetanus.
  • Pertussis is a highly contagious respiratory infection characterized by severe coughing fits. The DTaP vaccine contains antigens from Bordetella pertussis, which stimulate the production of antibodies to protect against pertussis infection.
  • Ongoing research aims to develop improved formulations of the DTaP vaccine with enhanced efficacy, safety, and duration of protection. This includes the development of newer adjuvants, delivery systems, and antigen combinations to optimize immune responses and reduce side effects.

Diphtheria, Tetanus, and Acellular Pertussis Combined Vaccine Market Dynamics

The key market dynamics that are shaping the global diphtheria, tetanus, and acellular pertussis combined vaccine market include:

Key Market Drivers:

  • Growing Awareness about Vaccination: The growing awareness of the importance of vaccination in preventing diseases like diphtheria, tetanus, and pertussis among parents, caregivers, and healthcare practitioners has led to a surge in demand for DTaP vaccines, fueled by educational campaigns and public health initiatives, resulting in market expansion.
  • Increasing Incidence of Pertussis: Pertussis outbreaks are a result of complex disease transmission and challenges in achieving herd immunity. Factors include waning immunity, incomplete vaccination coverage, and the evolution of Bordetella pertussis. Diagnosis is difficult, leading to treatment delays and increased risk of transmission. Rising cases of pertussis enable market growth.
  • Growing Healthcare Expenditure: The rise in healthcare expenditure in developing economies is driving investments in preventive measures, particularly vaccination programs. Healthcare providers, through partnerships with government agencies and international organizations, ensure widespread vaccine access and distribution, especially in underserved and remote areas. This growing commitment to preventive healthcare measures, particularly vaccination programs, is boosting market growth.
  • Growing advancements in vaccine formulations: Research is enhancing DTaP vaccine performance through innovative formulation strategies, enhancing adjuvants, antigen presentation systems, and delivery mechanisms, leading to improved stability, shelf-life, and administration ease, thereby promoting market expansion.

Key Challenges:

  • Vaccine Supply Shortages: Manufacturing disruptions, such as equipment malfunctions or quality control issues, can impede the production of DTaP vaccines, leading to inadequate supply levels. Supply chain disruptions, like transportation delays or storage issues, can exacerbate shortages and hinder timely distribution to healthcare facilities and vaccination sites, thereby challenging the manufacturing and supply of the combined vaccine.
  • Cold Chain Management Challenges: Cold chain management is crucial for vaccine efficacy, but temperature fluctuations can compromise effectiveness. Remote areas with limited access to electricity, refrigeration, and transportation infrastructure face additional challenges in cold chain management. Lack of proper handling protocols further restricts the combined diphtheria, tetanus, and acellular pertussis vaccine market.
  • Concerns Regarding Costing: DTaP vaccines are challenging to access in low- and middle-income countries due to resource constraints, limited availability, logistical hurdles, and affordability issues. This can impede vaccination efforts and increase immunization coverage disparities. Healthcare facilities struggle to maintain consistent stocks, leading to missed vaccination opportunities, especially for vulnerable children. Distribution logistics, particularly in remote or underserved areas, may hinder the combined vaccine market growth.

Key Trends:

  • Improved Vaccine Formulations: The DTaP vaccine is under continuous research to improve its formulations, safety, and protection duration. This involves exploring novel adjuvants, delivery mechanisms, and antigen combinations to optimize immune responses and minimize side effects, creating market growth opportunities.
  • Research and Development: Research is advancing DTaP vaccine technology to improve efficacy, safety, and accessibility. One innovation is mRNA vaccine technology, which uses synthetic mRNA molecules to produce specific antigens, triggering robust immune responses. This approach offers rapid development, scalability, and enhanced immunogenicity. Novel antigen delivery platforms like virus-like particles, liposomes, and nanoparticle carriers are also being explored.
  • Combination Vaccines: The development of combination vaccines, such as the DTaP vaccine, is gaining interest due to its potential to offer protection against a wider range of infectious diseases in a single formulation.

Global Diphtheria, Tetanus, and Acellular Pertussis Combined Vaccine Market Regional Analysis

Here is a more detailed regional analysis of the global diphtheria, tetanus, and acellular pertussis combined vaccine market:

North America:

  • North America is poised to maintain a substantial stake in the DTaP combined vaccine market, propelled by its robust healthcare infrastructure, elevated vaccination rates, and comprehensive government-driven immunization campaigns.
  • The region benefits from cutting-edge technological advancements, fortified by stringent regulatory frameworks, which collectively bolster the market's growth trajectory.
  • Moreover, heightened disease awareness among both healthcare professionals and the general populace further amplifies the demand for DTaP vaccines in North America.
  • This comprehensive ecosystem fosters a conducive environment for the continued expansion of the DTaP Combined Vaccine Market, ensuring widespread accessibility and efficacy of preventive healthcare measures against diphtheria, tetanus, and pertussis throughout the region.

Europe:

  • Europe stands out as a significant market for DTaP vaccines, distinguished by its well-established vaccination policies, comprehensive immunization coverage, and proactive approaches to disease prevention.
  • Europe's commitment to research and development (R&D) fosters innovation in vaccine technology and formulation. Increasing investments in R&D initiatives, alongside collaborations between public health agencies, academic institutions, and vaccine manufacturers, drive advancements in DTaP vaccine development.
  • Europe's proactive disease prevention strategies focus on early detection, surveillance, and response to infectious diseases, including those preventable by vaccination.
  • Strong partnerships between public health authorities and healthcare providers enhance disease surveillance efforts, enabling timely interventions to control disease outbreaks and minimize their impact on public health.

Asia Pacific:

  • Rapid urbanization and population growth in countries like China, India, and Japan further contribute to the expansion of the DTaP Combined Vaccine Market. As urban populations increase, so does the demand for healthcare services, including immunization.
  • Governments in these countries are implementing initiatives to strengthen healthcare infrastructure and improve access to healthcare services in both urban and rural areas, thereby facilitating the expansion of immunization programs.
  • Additionally, government initiatives aimed at enhancing healthcare infrastructure play a crucial role in driving market expansion.
  • Investments in healthcare facilities, vaccination clinics, and cold chain logistics contribute to the efficient delivery and distribution of DTaP vaccines, ensuring that they reach remote and underserved areas.

Global Diphtheria, Tetanus, and Acellular Pertussis Combined Vaccine Market: Segmentation Analysis

The Global Diphtheria, Tetanus, and Acellular Pertussis Combined Vaccine Market is segmented based on Product Type, Age Group, End User, And Geography.

Diphtheria, Tetanus, and Acellular Pertussis Combined Vaccine Market, By Product Type

  • DTaP Vaccines
  • TD Vaccines
  • Tdap Vaccines

Based on Product Type, the market is categorized into DTaP, TD, and Tdap. The DTaP segment dominated the global DTP vaccine market. The demand for DTaP and pertussis vaccines is driving global growth. WHO states immunization can prevent 3.5-5 million deaths annually. Since vaccines were introduced, few respiratory diphtheria cases have been reported by the CDC. Unvaccinated travelers face high infection risks, so governments mandate immunization for travelers visiting countries with infectious diseases. According to WHO In 2022, Coverage of a third dose of a vaccine protecting against diphtheria, tetanus, and pertussis (DTP3) recovered from 81% in 2021 to 84% in 2022. High birth rates, government initiatives, and insurance drive the DTaP vaccine market growth.

Diphtheria, Tetanus, and Acellular Pertussis Combined Vaccine Market, By Age Group

  • Adult Vaccines
  • Pediatric Vaccines

Based on Age Group, the DTP vaccines market is segmented into Pediatric Vaccines and Adult Vaccines. By age group, the market for vaccines for adults is expected to experience significant growth due to the increase in infectious diseases among adults. Moreover, the segment is likely to see an upsurge in growth due to advancements in research and development and a strong product pipeline during the forecast period. However, the pediatric segment currently dominates the market due to the high demand for DTP vaccines among infants. The pediatrics vaccines segment's potential size is based on the fact that the global birth rate is increasing, boosting the demand for pediatric vaccines.

Diphtheria, Tetanus, and Acellular Pertussis Combined Vaccine Market, By End-User

  • Hospitals
  • Clinics
  • Vaccination Centre

Based on End-User, the market is fragmented into Hospitals, Clinics, and Vaccination Centre. The hospital segment dominated the largest market share throughout the forecast period. Hospitals play a pivotal role as primary healthcare providers, offering a wide array of medical services, including immunization. As key end-users of DTaP vaccines, hospitals serve as vital hubs for administering preventive healthcare measures to individuals across all age groups, from newborns to adults. Their significance lies in their ability to provide comprehensive vaccination services, encompassing routine immunizations as well as rapid responses to disease outbreaks.

Diphtheria, Tetanus, and Acellular Pertussis Combined Vaccine Market, By Geography

  • North America
  • Europe
  • Asia Pacific
  • Rest of the World

Based on Geography, the Diphtheria, Tetanus, And Acellular Pertussis Combined Vaccine is classified into North America, Europe, Asia Pacific, and the Rest of the world. North America accounted for the largest market share of Diphtheria, Tetanus, and Acellular Pertussis Combined Vaccines. Well-established healthcare infrastructure, high vaccination rates, and robust immunization programs contribute to the dominance of the DTP vaccine market. Moreover, ongoing advancements in medical technology and strong regulatory frameworks further bolster market growth in this region.

Key Players

  • The "Diphtheria, Tetanus, and Acellular Pertussis Combined Vaccine Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are Johnson & Johnson, namely AJ Vaccines, and GlaxoSmithKline plc. Merck & Co. Inc., Sanofi, Bionet-Asia, Mass biologics, Meiji Holdings Co., Ltd., Panacea Biotech Ltd., and Serum Institute of India Pvt. Ltd. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

  • Diphtheria, Tetanus, and Acellular Pertussis Combined Vaccine Market Recent Developments
  • In October 2022, the FDA approved Boostrix for pregnant women in their third trimester to prevent pertussis in infants under 2 months old.
  • In June 2021, Merck and Sanofi's VAXELIS, the first and only six-in-one pediatric combination vaccine, is now available in the U.S. The vaccine is approved for use in children aged 6 weeks to 4 years to prevent diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B, and invasive disease due to Haemophilus influenzae type b.

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL DTaP COMBINED VACCINE MARKET

  • 1.1 Overview of the Market
  • 1.2 Scope of Report
  • 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

  • 3.1 Data Mining
  • 3.2 Validation
  • 3.3 Primary Interviews
  • 3.4 List of Data Sources

4 GLOBAL DTaP COMBINED VACCINE MARKET OUTLOOK

  • 4.1 Overview
  • 4.2 Market Dynamics
    • 4.2.1 Drivers
    • 4.2.2 Restraints
    • 4.2.3 Opportunities
  • 4.3 Porters Five Force Model
  • 4.4 Value Chain Analysis

5 GLOBAL DTaP COMBINED VACCINE MARKET, BY PRODUCT TYPE

  • 5.1 Overview
  • 5.2 DTaP
  • 5.3 TD
  • 5.4 Tdap

6 GLOBAL DTaP COMBINED VACCINE MARKET, BY AGE GROUP

  • 6.1 Overview
  • 6.2 Adult
  • 6.3 Pediatric

7 GLOBAL DTaP COMBINED VACCINE MARKET, BY END USER

  • 7.1 Overview
  • 7.2 Hospitals
  • 7.3 Clinics
  • 7.4 Vaccination Centers

8 GLOBAL DTaP COMBINED VACCINE MARKET, BY GEOGRAPHY

  • 8.1 Overview
  • 8.2 North America
    • 8.2.1 U.S.
    • 8.2.2 Canada
    • 8.2.3 Mexico
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 U.K.
    • 8.3.3 France
    • 8.3.4 Rest of Europe
  • 8.4 Asia Pacific
    • 8.4.1 China
    • 8.4.2 Japan
    • 8.4.3 India
    • 8.4.4 Rest of Asia Pacific
  • 8.5 Rest of the World
    • 8.5.1 Latin America
    • 8.5.2 Middle East and Africa

9 GLOBAL DTaP COMBINED VACCINE MARKET COMPETITIVE LANDSCAPE

  • 9.1 Overview
  • 9.2 Company Market Ranking
  • 9.3 Key Development Strategies

10 COMPANY PROFILES

  • 10.1 Bionet-Asia
    • 10.1.1 Overview
    • 10.1.2 Financial Performance
    • 10.1.3 Product Outlook
    • 10.1.4 Key Developments
  • 10.2 Johnson & Johnson
    • 10.2.1 Overview
    • 10.2.2 Financial Performance
    • 10.2.3 Product Outlook
    • 10.2.4 Key Developments
  • 10.3 GlaxoSmithKline plc
    • 10.3.1 Overview
    • 10.3.2 Financial Performance
    • 10.3.3 Product Outlook
    • 10.3.4 Key Developments
  • 10.4 Mass biologics
    • 10.4.1 Overview
    • 10.4.2 Financial Performance
    • 10.4.3 Product Outlook
    • 10.4.4 Key Developments
  • 10.5 Meiji Holdings Co., Ltd.
    • 10.5.1 Overview
    • 10.5.2 Financial Performance
    • 10.5.3 Product Outlook
    • 10.5.4 Key Developments
  • 10.6 Merck & Co., Inc.
    • 10.6.1 Overview
    • 10.6.2 Financial Performance
    • 10.6.3 Product Outlook
    • 10.6.4 Key Developments
  • 10.7 Panacea Biotech Ltd.
    • 10.7.1 Overview
    • 10.7.2 Financial Performance
    • 10.7.3 Product Outlook
    • 10.7.4 Key Developments
  • 10.8 Sanofi
    • 10.8.1 Overview
    • 10.8.2 Financial Performance
    • 10.8.3 Product Outlook
    • 10.8.4 Key Developments
  • 10.9 Serum Institute of India Pvt. Ltd.
    • 10.9.1 Overview
    • 10.9.2 Financial Performance
    • 10.9.3 Product Outlook
    • 10.9.4 Key Developments
  • 10.10 namely AJ Vaccines
    • 10.10.1 Overview
    • 10.10.2 Financial Performance
    • 10.10.3 Product Outlook
    • 10.10.4 Key Developments

11 Appendix

  • 11.1 Related Research